A retrospective assessment of two randomized controlled trials confirmed the positive relationship between tTMB and bTMB (Spearman’s rank correlation, r = 0.64, 95% CI 0.56–0.71) and revealed that bTMB could identify patients with NSCLC sensitive to atezolizumab with good repeatability and predict PFS independently, regardless of PD-L1 expression levels [96]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.